.png?width=700&name=New-ATE-Logo2019%20(1).png)
Advancing mRNA and CircRNA-based
Vaccines and Therapeutics in CMC:
From Process Development to Analytics
Presenter:
Shanshan Wang, PhD earned her doctoral degree from Heidelberg University, Germany, and has over a decade of research experience in molecular biology and biochemistry, with six peer-reviewed publications to her name. She also brings more than six years of industrial expertise in biologics R&D and CMC.
Currently, Wang leads the RNA drug substance team at the RNA Center of Excellence at Zhejiang Innoforce Pharmaceutical. In this role, she oversees process development and technological innovation for plasmid and RNA platforms. Her responsibilities span from molecule design and optimization to process development, technology transfer, manufacturing support, and IND dossier preparation.
Wang has successfully managed numerous client and internal projects, including an end-to-end mRNA vaccine program that achieved FDA IND approval, demonstrating her expertise and leadership in advancing RNA-based therapeutics.
